Key result
Antiplatelet drugs did not affect systolic blood pressure within 12 months of use, though they may benefit patients by reducing proteinuria.
Why the study?
The effects of antiplatelet drugs on proteinuria, renal function, and blood pressure in patients with diabetic nephropathy were unclear.
Do antiplatelet drugs improve proteinuria, renal function, and blood pressure in patients with diabetic nephropathy?
Meta-Analysis
Do antiplatelet drugs improve proteinuria, renal function, and blood pressure in patients with diabetic nephropathy?
Antiplatelet drugs may benefit patients with diabetic nephropathy by reducing proteinuria, though they do not significantly affect blood pressure within 12 months.
Answers are grounded in this paper and cite their sources.
No systolic BP effect supports antiplatelet safety in kidney disease; confirms neutral impact while extending proteinuria reduction evidence.
AIMS: To evaluate the effects of antiplatelet drugs on proteinuria, renal function, and blood pressure (BP) in patients with diabetic nephropathy (DN). MATERIALS AND METHODS: A meta-analysis of randomized controlled trials (RCTs) was performed. Relevant RCTs were identified by a systematic search of the PubMed, Cochrane Library, and Embase databases. A random-effects model was applied to pool the results. CONCLUSION: Antiplatelet drugs may benefit patients with DN by reducing proteinuria. The long-term effects of antiplatelet drugs on the progression of DN warrant further evaluation. .
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) conducted a meta-analysis in diabetic nephropathy. Antiplatelet drugs was evaluated on systolic blood pressure (WMD 1.53, p=0.35). Antiplatelet drugs did not affect systolic blood pressure within 12 months of use, though they may benefit patients by reducing proteinuria.
Synapse has enriched 10 related papers. Consider them for comparative context: